Corbus Pretax Profit Margin from 2010 to 2024

CRBP Stock  USD 37.74  0.04  0.11%   
Corbus Pharmaceuticals Pretax Profit Margin yearly trend continues to be relatively stable with very little volatility. Pretax Profit Margin is likely to grow to -56.55 this year. During the period from 2010 to 2024, Corbus Pharmaceuticals Pretax Profit Margin destribution of quarterly values had r-value of (0.76) from its regression line and median of (13.65). View All Fundamentals
 
Pretax Profit Margin  
First Reported
2010-12-31
Previous Quarter
(59.53)
Current Value
(56.55)
Quarterly Volatility
19.74706067
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Corbus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corbus main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 2.8 M or Selling General Administrative of 14.6 B, as well as many exotic indicators such as Price To Sales Ratio of 93.82, Dividend Yield of 0.0 or Days Sales Outstanding of 191. Corbus financial statements analysis is a perfect complement when working with Corbus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Corbus Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Corbus Pharmaceuticals Technical models . Check out the analysis of Corbus Pharmaceuticals Correlation against competitors.

Latest Corbus Pharmaceuticals' Pretax Profit Margin Growth Pattern

Below is the plot of the Pretax Profit Margin of Corbus Pharmaceuticals Holding over the last few years. It is Corbus Pharmaceuticals' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corbus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Pretax Profit Margin10 Years Trend
Slightly volatile
   Pretax Profit Margin   
       Timeline  

Corbus Pretax Profit Margin Regression Statistics

Arithmetic Mean(24.47)
Coefficient Of Variation(80.70)
Mean Deviation16.74
Median(13.65)
Standard Deviation19.75
Sample Variance389.95
Range57.5531
R-Value(0.76)
Mean Square Error177.11
R-Squared0.58
Significance0.001
Slope(3.36)
Total Sum of Squares5,459

Corbus Pretax Profit Margin History

2024 -56.55
2023 -59.53
2021 -51.76
2020 -28.26
2019 -1.98
2018 -11.54
2017 -13.29

About Corbus Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Corbus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Corbus Pharmaceuticals investors use historical funamental indicators, such as Corbus Pharmaceuticals's Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although Corbus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Corbus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Corbus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Corbus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Corbus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Pretax Profit Margin(59.53)(56.55)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Corbus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Corbus Pharmaceuticals' short interest history, or implied volatility extrapolated from Corbus Pharmaceuticals options trading.

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Corbus Stock

  0.65EVO Evotec SE ADR Earnings Call TomorrowPairCorr
  0.57PCRX Pacira Pharmaceuticals Financial Report 1st of May 2024 PairCorr
  0.44MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Corbus Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corbus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corbus Pharmaceuticals Holding Stock. Highlighted below are key reports to facilitate an investment decision about Corbus Pharmaceuticals Holding Stock:
Check out the analysis of Corbus Pharmaceuticals Correlation against competitors.
Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Corbus Stock analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.31)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.60)
Return On Equity
(3.42)
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.